KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Revenue for 16 consecutive years, with $451.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 51.6% to $451.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 37.55% increase, with the full-year FY2025 number at $1.4 billion, up 37.55% from a year prior.
  • Revenue was $451.8 million for Q4 2025 at Halozyme Therapeutics, up from $354.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $451.8 million in Q4 2025 to a low of $89.0 million in Q1 2021.
  • A 5-year average of $217.2 million and a median of $212.5 million in 2022 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 251.12% in 2021; the steepest drop was 16.19% in 2021.
  • Halozyme Therapeutics' Revenue stood at $102.0 million in 2021, then soared by 77.93% to $181.5 million in 2022, then rose by 26.75% to $230.0 million in 2023, then increased by 29.55% to $298.0 million in 2024, then soared by 51.6% to $451.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Revenue are $451.8 million (Q4 2025), $354.3 million (Q3 2025), and $325.7 million (Q2 2025).